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26 In the course of our research of vanadium-containing complexes, two oxidovanadium 
27 complexes containing vanadium(V) and (IV) core with 4-aminobenzoic acid and/or peroxo 
28 anion as ligands were synthesized and characterized by elemental analysis, conductivity 
29 measurements, thermogravimetric analysis, and 1H NMR, EPR, FTIR, UV/Vis 
30 spectroscopies. Their compositions and geometrical structures 
31 (([VO(O2)(C7H6NO2)(H2O)].H2O, [VO(C7H6NO2)2H2O]) were supported by experimental 
32 data and theoretical studies (Density functional theory, DFT). The complexes were 
33 evaluated in vitro as phosphatase inhibitors (alkaline and acid enzymes) being considered 
34 as potential pharmaceutical agents under over-expression of those biochemical markers. 
35 The effect achieved was then analysed through FTIR spectroscopy. Changes in the finger 
36 print substrate bands as well as induced conformational changes on phosphatases enzymes 
37 secondary structure were further examined. Eventually albumin interactions experiments 
38 were performed in order to derive their bioavailability. 
39














































































































































49 Over recent years, several developments in the field of medicinal bioinorganic chemistry 
50 have taken place leading to transformations in parent drugs distribution through structural 
51 modifications of the pharmacological ligands by means of preparation of corresponding 
52 metal-based drugs. Transition metal complexes in particular present considerably more 
53 advantages compared to organic-based drugs due to the variability seen regarding 
54 coordination numbers, geometries, redox states, ligand substitution and structural diversity. 
55 Coordination to a metal ion usually leads to charge addition, and specific conformations 
56 that often ameliorate the biological activity of organic-based drugs. This novel strategy for 
57 therapy or diagnosis has come to the forefront. 1,2 There are many examples in which a 
58 synergistic effect is observed resulting in improved biological activity. Vanadium is 
59 included in this large list of metals with physiological roles; and it can be in its higher 
60 oxidation states V (V, d0) and V (IV, d1) in biological systems forming anionic or cationic 
61 complexes at physiological pH. Those oxidation states easily convert to each other playing 
62 an important role in the balance of reactive oxygen species which determine their intra or 
63 extra-cellular composition. In solution, vanadium exhibits rich chemistry along with its 
64 redox behaviour including the ability to form complexes with a great variety of biological 
65 molecules (ATP, ribose, glutathione, amino acids, etc). Vanadium chemical affinity to 
66 oxygen, nitrogen or sulphur atoms, as well as its flexibility in coordination geometry 
67 (tetrahedral, octahedral, to trigonal pentagonal-bipyramid for V(V), and also square 
68 pyramidal for V(IV)) allows it to form stable or transition state complexes to participate in 
69 biological process. 3,4 It was not until the 1960s that vanadium chemistry and biochemistry 
70 attracted interest with two major aspects being considered: first, biological systems and 
71 vanadium-based compounds have pharmaceutical and industrial applications; second, 





































































































































72 vanadium coordination complexes have further been recognized as efficient catalysts in 
73 several oxidation processes of industrial interest5 including vanadium(V) oxo and peroxo 
74 complexes containing ligands similar to 4-aminobenzoic acid.6 Vanadium compounds have 
75 been studied in relation to their pharmacological activities including antihyperlipidemic, 
76 anti-obesity, diuretic, antihypertensive and anticancer drugs, among others.3.4 It was the 
77 vanadium antidiabetic effect in particular which has been attributed to the structural 
78 similarity between phosphate and vanadate anions. As a consequence, several vanadium 
79 species and organic derived compounds were successfully proven as antidiabetic agents. 
80 Their actions may include (i) enhancement of the glucose transport, (ii) inhibition of 
81 gluconeogenesis, lipolysis, and glycogenolysis in the liver and (iii) inhibition of protein 
82 tyrosine phosphatase (PTPase) and alkaline phosphatase (ALP). In this sense, vanadium 
83 dipicolinate complexes were proven to behave as insulin-mimetic compounds.7.8 
84 Phosphatases display a number of physiological functions and their selective inhibitors 
85 have potential therapeutic roles. PTP1B (Protein tyrosine phosphatases 1B) belongs to a 
86 family of enzymes that catalyse the dephosphorylation of tyrosine (Tyr)-phosphorylated 
87 proteins. This phosphatase is involved in the deregulation of insulin and leptin signals 
88 which show significant for diabetes and obesity. These are part of the reasons why PTP1B 
89 becomes a therapeutic target encouraging selective inhibitors research.9 There are many 
90 examples including alkaline (ALP) and acid (AcP) phosphatases. While the over-
91 expression of non-specific alkaline phosphatase tissue is associated with hypophosphatasia, 
92 hydroxyapatite deposition disorder, vascular and arterial calcification, and hyperthyroidism 
93 condition10, the elevated levels in serum of acid phosphatase are on the contrary correlated 
94 with osteoporosis and metabolic bone malignancies as well as cancer with bone metastases. 
95 AcP has indeed been identified as a relevant drug target for the treatment of bone-
96 associated diseases.11 





































































































































97 Vanadium species are recognized as phosphatase inhibitors. Orthovanadate (VO43-) 
98 behaves as a strong inhibitor of Na+, K+-ATPase, PTPase and ALP and also of potato and 
99 wheat germ acid phosphatases.12 Despite the great effect showed by vanadium species, 
100 reported side effects prompted researchers to prove others vanadium organic derivative 
101 compounds as inhibitors. In effect it can be seen in the literature 3,12 that several vanadium 
102 compounds have been tested as phosphatase inhibitors. They mainly included 
103 oxidovanadium(V) and (IV) cations and bisperoxidovanadium complexes; reports 
104 pertaining to peroxidovanadium complexes, specifically those concerning AcP are, 
105 however, scarce.
106 All these observations encourage us to prepare, characterize and test in vitro the behaviour 
107 of two vanadium complexes with 4-aminobenzoic acid as ligand, based in the sequential 
108 interest of our research group in the development and study of new phosphatase inhibitors 
109 with promising bioactivities.
110 Finally, studies on protein carrier using fluorescence albumin experiments were performed 
111 in order to assess if the complexes can interact and be delivered by albumin at 
112 physiological conditions.
113
114 2. Materials and methods
115
116 Vanadium(V) oxide (Anedra), solid oxidovanadium(IV) sulfate pentahydrate (Merck)  and 
117 4-aminobenzoic acid (Acros Organics) were used as supplied. Peroxido species was 
118 prepared according to Fantus et al.13Bovine Serum Albumin BSA (A-6003, essentially 
119 fatty acid-free), bovine intestinal ALP (EC 3.13.1, calf intestinal mucose) and acid 
120 phosphatase AcP (EC 3.1.3.2, potato source) were obtained from Sigma Chemical 





































































































































121 Company (St. Louis, MO) and used as supplied. All the chemicals used were from 
122 analytical grade. Elemental analysis for carbon, nitrogen and hydrogen was performed 
123 using a Carlo Erba EA1108 analyzer. Vanadium content was determined by the 
124 tungstophosphovanadic method. A Shimadzu system (model TG-50 and DTA-50), 
125 working in an oxygen flow of 50 mL.min-1 and at a heating rate of 10 °C.min-1 has been 
126 used for the thermogravimetric analysis. Sample quantities ranged between 10 and 20 mg. 
127 Al2O3 was used as a DTA standard.
128 FTIR spectra of powdered samples as pressed KBr pellets were measured with a 
129 Bruker IFS 66 FTIR-spectrophotometer in the 4000-400 cm-1 wavenumber range. Spectra 
130 were recorded with a wavenumber resolution of 4 cm-1 and 64 scans were averaged for 
131 each spectrum. The data were analyzed using OPUS program (Bruker Optics, USA).
132 EPR spectra in solid state were registered in an EMX Bruker instrument, working at 
133 X-band, at low temperature (77K) or at room temperature (298K). DPPH was used as 
134 calibrant. Usual instrument parameters: Power = 20.17 mW; frequency 9.42 GHz; 
135 modulation frequency 100 MHz; modulation amplitude 15G; time constant 20.48 ms.
136 UV/Vis spectra were recorded with a Shimadzu 2600/2700 spectrophotometer. This 
137 instrument was also used to collect the diffuse reflectance spectra, employing MgO as a 
138 standard for those experiments. Fluorescence spectra were obtained using a Shimadzu 
139 (RF6000) luminescence spectrometer equipped with a pulsed xenon lamp.
140
141 2.1.  Syntheses of complexes
142
143 [VO(O2)L(H2O)].H2O (L= C7H6NO2)
144





































































































































145 Vanadium(V) oxide (0.099 g; 0.54 mmol) was dissolved in 10 ml of hot water by adding 
146 KOH 1M with heating and stirring until complete dissolution. The resulting clear yellow 
147 solution was stirred at 0oC and the pH was adjusted at 4 (with drops of HCl 1M). To this 
148 solution, 0.15 g (1.1 mmol) of 4-aminobenzoic acid dissolved in 25 ml of distilled water 
149 was added followed by the addition of 3 mL of 10% H2O2 to give a red solution. The 
150 solution was left stirring (24h) and its volume was reduced by evaporation of the solvent at 
151 60oC to ca. 70%. The precipitated brownish orange powder was filtered out and allowed to 
152 dry at room temperature. Elemental analysis: Calc.: 31.46% C, 5.24% N, 3.74% H, 19.10% 
153 V; Exp.: 31.08% C, 4.98% N, 3.66% H, 18.81% V. TG curve: loss of one water molecule 
154 up to 160 ºC (exp = 5.98 % and calc = 6.74 %, DTA, endo 50 ºC). This temperature is 
155 indicative that the water molecule is not bonded to the metal, being hydration water. The 
156 complex is soluble in DMSO and DMF, partially in other organic solvents and insoluble in 
157 H2O. For the biological measurements the complex was initially dissolved in DMSO and, 
158 thereafter a solution of the complex in a mixture of DMSO:water (5% in DMSO) was used. 
159 The values of the molar conductivities were: =16.2 S.cm2.mol-1 (7.14 x 10-4 M, 
160 methanol) and =21.69 S.cm2.mol-1 (5.53 x 10-4 M, DMF). It can be considered that the 
161 compound do not dissociate in solution, since for a 1:1 electrolyte, the  values should be 
162 70 S.cm2.mol-1 in those solvents.14 1H NMR spectra: Exp (Calc): H aromatic: H2a=7.72 
163 (7.73) ppm, H3a=6.62(6.25) ppm, H5a= 6.65(6.31) ppm, H6a=7.75(7.55) ppm.15 
164
165 [VOL2H2O] (L= C7H6NO2)
166
167 To obtain this complex, 0.253 g (1 mmol) of VOSO4·5H2O were dissolved in 5mL of 
168 distilled water. It was then dropwise added to a solution of 0.274 g (2 mmol) of 4-





































































































































169 aminobenzoic acid dissolved in 45 mL of distilled water. To this solution, an aqueous 
170 NaOH 1M solution was added, under continuous stirring to a final pH value of 5. The 
171 resulting dark green solution was kept under stirring for 4 h. After that, a green precipitate 
172 was formed which was separated by centrifugation, washed several times and dried in an 
173 oven (60 oC). Elemental analysis: Calc.: 47.06 %C, 7.84 %N, 3.92 %H, 14.28 %V; Exp: 
174 47.52 %C, 8.20 %N, 3.70 %H, 14.25 %V. TG curve: one water molecule is lost at 180 ºC 
175 (exp = 4.87 % and calc = 5.04 %, DTA, endo). In this case the high dehydration 
176 temperature value indicated that the water molecule is coordinated to the metal ion. The 
177 values of the molar conductivities were: =18.9 S.cm2.mol-1 (7.14 x 10-4 M, methanol) and 
178 =33.55 S.cm2.mol-1 (4.47 x 10-4 M, DMF). It can be considered that the compound do not 
179 dissociate in solution, since for a 1:1 electrolyte, the  values should be 70 S.cm2.mol-1 in 
180 those solvents.14 1H NMR spectra: Exp (Calc): H aromatic: H2a=7.72 (7.44) ppm, 
181 H2a´=7.72 (7.58) ppm, H3a=6.62(6.23) ppm, H3a´=6.62(6.19) ppm, H5a= 6.65(6.25) ppm, 
182 H5a´= 6.65(6.30) ppm, H6a=7.75(7.60) ppm , H6a´=7.75(7.67) ppm.15
183
184 2.2.  Phosphatases Inhibition. In vitro assays.
185 Acid phosphatase 
186
187 Acid phosphatase inhibition test was performed according to Blum and Schwedt 
188 procedures.16 The compounds solutions were prepared by diluting the stock solutions 
189 prepared in DMSO with acetate buffer (pH=5.6) to give final concentrations of 10 to 500 
190 M. A volume of 0.50 mL of complex solution (10-500 M) was mixed with 0.10 mL of 
191 the enzyme solution and 1.00 mL of buffer. The mixture was kept at 37C for 20 min 
192 (incubation time). After starting the reaction by adding 0.10 mL of the substrate solution 





































































































































193 (p-nitrophenylphosphate (p-NPP)), the tube was kept at 37C for more 20 min. The 
194 reaction was stopped with the addition of 0.50 mL of a 0.5 M sodium hydroxide solution. 
195 The enzymatic activity was finally calculated by measuring the absorbance of p-
196 nitrophenol at 405 nm against a blank prepared without the enzyme. Three independent 
197 replicates of each point were measured. The 100% of the enzyme activity is assigned to a 
198 basal measurement containing all the reaction media including the same volume of DMSO 
199 in all the experiments. It is worthy to mention that the presence of DMSO (0.5%) did not 
200 affect the enzyme activity.
201
202 Alkaline phosphatase 
203
204 The basis of the method is similar to that of AcP but differs in the pH value of the reaction 
205 medium. Again, the conversion of the substrate p-NPP to p-nitrophenol was monitored by 
206 the absorbance changes at 405 nm. Briefly, the experimental conditions for ALP specific 
207 activity measurement were as follows: 1 g/mL of bovine intestinal ALP and 5 mM of p-
208 NPP were dissolved in the incubation buffer (55 mM glycine +0.55 mM MgCl2, pH=10.5) 
209 and held for 10 min. The effects of the compounds were determined by addition of 
210 different concentrations (10-500 M) of each one to the pre-incubated mixture. The 
211 solutions of the complexes were prepared in DMSO before adding the buffer to obtain the 
212 desired final concentrations. The effect of each concentration was tested at least in 
213 triplicate in three different experiments.
214





































































































































215 2.3 Infrared spectroscopy: analysis of the substrate (p-nitrophenylphosphate) 
216 vibrational bands and the secondary structure of the phosphatases at the inhibition 
217 experimental conditions.
218
219 For the substrate analysis, FTIR spectra of the freeze-dried powdered samples were 
220 collected. The samples were prepared at the same experimental conditions than the in vitro 
221 experiments. Then, to investigate the ability of the compounds to produce conformational 
222 changes in the phosphatases enzymes, solution spectra were measured under the same 
223 experimental conditions of inhibitory experiments but without the addition of p-NPP. FT-
224 IR/ATR spectra were recorded with a Bruker IFS 66 FTIR-spectrophotometer from 4000 
225 to 400 cm-1 equipped with an internal reflectance accessory using ZnSe crystal designed to 
226 have one angle of light incidence of 45o. Spectra were recorded at room temperature with a 
227 spectral resolution of 4 cm-1. To improve the signal-to-noise ratio, 200 scans were averaged 
228 for each spectrum and the procedure was performed as reported previously.17 According to 
229 the results obtained in the previous section, the FTIR/ATR spectra of the buffer solutions 
230 (acetate buffer and glycine for AcP and ALP, respectively), AcP and ALP (at the same 
231 concentrations as the inhibition tests) and the systems: (i) ALP with 4-aminobenzoic acid 
232 (500 M), V(IV)O2+ (250 M), oxidovanadium(IV) (500 M) and peroxidovanadium(V) 
233 compounds (500 M), (ii) AcP with 4-aminobenzoic acid (500 M), V(IV)O2+ (250 M), 
234 oxidovanadium(IV) (250 M) and peroxidovanadium(V) (500 M) compounds were taken 
235 independently, and analyzed. Then, the absorbance values of the buffer solution were 
236 subtracted from the values of the protein solution to get the FT-IR spectra of the protein. 
237 All spectra were vector normalized in the whole range (4000-500 cm-1) and were obtained 
238 after collecting and averaging 200 scans. All analyses were performed in three independent 
239 experiments, and the results were reported as averages of these replicates. The 





































































































































240 determination of the secondary structure was carried out on the basis of the procedure 
241 previously described.17 The Amide I region (1700-1600 cm-1) was used to investigate the 
242 secondary structure of the phosphatases in a quantitative manner. The frequencies, the 
243 number of peaks to be fitted, and the half-width of each peak to start a least square iterative 
244 curve-fitting procedures were those obtained from the second derivative of the original 
245 spectra. The areas of the bands were calculated by integration of the corresponding fitted 
246 band. A straight baseline passing through the ordinates at 1700 cm-1 and 1600 cm-1 was 
247 adjusted as an additional parameter to obtain the best fit. The curve-fitting procedure was 
248 performed by stepwise iterative adjustment towards a minimum root mean-square error of 
249 the different parameters determining the shape and position of the absorption peaks. It was 
250 carried out by assuming an initial mixed Lorentzian-Gaussian line-shape function, with full 
251 width band at half height (FWHH) of 10-15 cm-1 and a maximum resolution factor. 
252 Baseline corrections, normalization, derivation, curve fitting and area calculation were 
253 carried out by means of Grams/32 (Galactic Industries Corporation, USA) software, OPUS 
254 3.1, and Perkin-Elmer software. The resulting fitted curve was analyzed taking into 
255 account the following assignments: β-sheets, 1637-1613 cm-1; solvated helix, 1625-1637 
256 cm-1, random coil, 1645-1637 cm-1, α-helix, 1658-1650 cm-1, turns, 1673-1666 cm-1 and β-
257 antiparallel, 1695-1675 cm-1. In order to calculate the percentage contribution of the 
258 different types of conformations to the area of all the components, bands assigned to a 
259 given conformation were summed and divided by the total Amide I area. 
260
261 2.4.  Albumin interaction
262
263 Fluorescence quenching experiments 
264





































































































































265 Bovine serum albumin (BSA) was dissolved in 0.1M Tris-HCl buffer (pH 7.4) to attain a 
266 final concentration of 6 μM. The solutions of the studied compounds were added drop-wise 
267 to the above 6 μM BSA preparation to ensure the formation of a homogeneous solution and 
268 to obtain the desired concentration of 0-100 μM. Adequate solubility was reached under 
269 these experimental conditions and the compounds did not showed significant fluorescence 
270 that could interfere with the measurements. For each sample and concentration, three 
271 independent replicates were performed at 25 ºC and 37 ºC. BSA 6 μM was titrated by 
272 successive additions of complex solutions from 0 to 100 μM and the fluorescence intensity 
273 was measured (excitation at 280 nm and emission at 348 nm). All the fluorescence 
274 quenching data were analyzed according to previous studies performed in the laboratory by 
275 applying a traditional mathematical procedure. The fluorescence-quenching mechanism 
276 has been analyzed using the Stern-Volmer eq. (1).18   
277 Fo/F = 1 + Ksv [Q]                          eq.  (1)
278 where Fo is the steady-state fluorescence intensity of BSA alone while F is the observed 
279 intensity upon increasing the quencher concentration, Ksv is the Stern-Volmer quenching 
280 constant and [Q] is the quencher concentration. Usually, the curve of Fo/F vs [Q] is linear if 
281 the type of quenching involves a unique process: static or dynamic. Static quenching is due 
282 to the complex formation between the fluorophore and the quencher. It can be 
283 distinguished from collision effects because generally the Ksv value is higher than the value 
284 of the dynamic quenching constant (Kq). Considering that Kq= Ksv/0 (where 0= 10-8 s is 
285 the average lifetime of the biomolecule without quencher), this constant can be estimated 
286 and compared with the maximum diffusion collision quenching rate constant (reference 
287 value from the literature) which is 2 x 10-10 M-1 s-1. If the Ksv value is greater, then a 
288 mechanism of interaction through the complex formation can be proposed. Otherwise it 
289 would be a collisional quenching. If the quenching is static, it is assumed that there are 





































































































































290 specific binding sites. These binding sites, and their association constants, were estimated 
291 using the following mathematical relationship:
292 log [(F0-F)/F)] = log Kb + n log [Q]    eq. (2)
293 where Kb is the binding constant and n is the average number of biding site per protein 
294 molecule.
295 To obtain information about the type of interaction, the thermodynamic parameters were 
296 calculated using Van´t Hoff equation18:
297 ln (Kb2/Kb1) = -H0/R (1/T2-1/T1)                        eq. (3)
298 where T1 and T2 are the absolute temperatures at which Kb1 and Kb2  were determined. The 
299 standard free energy change (G0) and the standard free entropy change (S0) were 
300 evaluated according to the well-known thermodynamic relationships:
301
302 G0 = - RT ln Kb                                            eq. (4)
303 S0 = (H0-G0)/T                                         eq. (5) 
304
305 3D fluorescence spectra
306
307 The three-dimensional fluorescence spectra were performed under the following 
308 experimental conditions: (i) Emission wavelength was recorded between 200 and 600 nm, 
309 (ii) Excitation wavelength from 200-400 (5 nm of increment), (iii) the number of scanning 
310 curves was 15. Other scanning parameters were just the same to those of the fluorescence 
311 quenching spectra.





































































































































312 2.5. Computational methods
313
314 The absence of X-ray single-crystal analysis led us to characterize the structures of 
315 the complexes using Gaussian 09 program19 and the density functional theory (DFT) 
316 calculations which have demonstrated a good correlation with experimental data for 
317 coordination metal complexes. Truhlar model M06L20 was used to optimize the geometries 
318 based on a meta-GGA functional. Basis sets of triple-zeta quality with polarized (TZVP) 
319 functions were used for all atoms. The initial structures of the complexes were modeled as 
320 isolated molecules according to the experimental data for the complexes and taking into 
321 account the solvent environment using the conducting polarizable continuous model 
322 (CPCM) as implemented in the software package. The ground state geometries were 
323 optimized using the method mentioned above in the gas phase. The vibrational analysis 
324 were performed at the same level of theory in order to get a minimum on the potential 
325 energy surface, and then, calculation of IR and Raman frequencies were considered for 
326 supporting the characterization of the complexes. UV-vis spectra were calculated with the 
327 time-dependent density functional theory (TD-DFT) formalism21 using the well-known 
328 functional B3LYP22,23 and a split-valence triple zeta basis set (6-311+g*). Solution spectra 
329 were carried out simulating solvent effect using the same model described above. Water 
330 and DMF were taken into account for optimization and UV/Vis, respectively. 
331
332 3. Results and discussion
333
334 Experimental data (elemental analysis, thermogravimetric, conductimetry, 1H NMR), 
335 physicochemical characterizations (see above) together with theoretical optimized 
336 structures analysis, let us to propose the following structures to the studied complexes, 





































































































































337 showed in Figure 1. In the peroxido complex [VO(O2)L(H2O)]·H2O, the vanadium center 
338 is located in a pentagonal pyramid with a bidentate coordination mode of the peroxo and 
339 the carboxylate group of the 4-aminobenzoate ligand. A water molecule occupied the 
340 equatorial position forming a distorted pentagonal plane (Figure 1A). For the 
341 oxidovanadium complex cis-[VOL2H2O], the oxidovanadium(IV) cation shows a distorted 
342 octahedral structure being both 4-aminobenzoate ligands in a bidentate coordination mode 
343 through the carboxylate groups and a water molecule complete the six-coordination sphere. 
344 From the two calculated possible conformations (cis- and trans-) the cis-one was in 
345 correspondence with the experimental results (see below), showed in Figure 1B (see Figure 
346 S1 for trans structure). Characteristic bond lengths and angles around the vanadium atom 
347 for the complexes are depicted in Table 1.
348
349 3.1.  Infrared Spectra
350
351 The FTIR spectrum was analyzed in comparison with the corresponding spectrum of 4-
352 aminobenzoic acid which has been extensively studied.15 The most characteristic bands are 
353 shown in Table 2. (Figure S2).
354 The FTIR spectra of the complexes display typical features of the coordinated 
355 ligand when they were compared with the spectra of 4-aminobenzoic acid and its sodium 
356 salt. The calculated spectra for [VO(O2)L(H2O)]·H2O and [VOL2H2O] were used to 
357 support empirical assignment of the vibrational bands. Table 2 shows that the experimental 
358 and the selected calculated wavenumbers for the compounds are in good agreement even 
359 without the use of scaling factors. The differences observed are related to the fact that the 





































































































































360 calculations for the isolated molecule have been performed in gas phase and the 
361 experimental spectra correspond to solid samples.
362 As it is well known, the formation of an ionic salt from a carboxylic acid produces 
363 two bands related to the ionic form of the carboxylate group corresponding to the 
364 asymmetric as(COO-) and symmetric s(COO-) stretching modes.24 Thus, the 1680 cm-1 
365 band of the (C=O) stretching of the carboxylic acid group is splitted into two components 
366 at 1529 cm-1 and 1397 cm-1 in the sodium salt giving a  as(COO-)-s(COO-)) value of 
367 132 cm-1. Other characteristic bands are due to the presence of the -NH2 group in the 
368 molecules of both (the free acid and the sodium salt). They appear in the ranges of 1620-
369 1635 cm-1 for the (NH2) and 1070-1085 cm-1 for the NC) vibrational modes. 
370 Analyzing the FTIR spectrum of the cis-oxidovanadium(IV) complex,  two new bands at 
371 1506 cm-1 and 1408 cm-1 can be clearly seen. These bands can be assigned to the 
372 asymmetric stretching (as(COO-)) and symmetrical stretching (s(COO-)) vibrational 
373 modes, respectively. The same vibrational modes appear at 1525 cm-1 and 1429 cm-1 in the 
374 peroxidovanadium(V) complex. In both cases the calculated  values 98 and 96 cm-1, 
375 respectively) are lower than the  of the sodium salt suggesting a bidentate type of 
376 coordination of the carboxylate group to vanadium.24 In addition, the V=O) stretching 
377 bands can be detected. They appear at 965 cm-1 for the oxidovanadium(IV) complex. It 
378 was established that the decrease of V=O) stretching frequency which occurs in 
379 oxidovanadium complexes is a measure of the donor ligand capacity. From the differences 
380 observed between the calculated and experimental V=O) frequencies values of the 
381 oxidovanadium(IV) complex, the lowest value is shown by the cis- configuration which 
382 has a longer V=O distance (see electronic supplementary information). This is in 
383 correspondence with the presence of one water molecule in the equatorial plane of the 
384 oxidovanadium(IV) complex having less electron donation ability than the carboxylate 





































































































































385 group as it was expected.25 For the peroxidovanadium(V) complex (with a shorter bond 
386 length, see Table 1) this band can be detected at higher wavenumbers (998 cm-1) and has 
387 been assigned to a combined vibration of V=O and O-O bonds due to their mutual 
388 interactions. Additionally, the vibrational modes corresponding to the characteristic 
389 stretches V-O2) of the peroxo moiety can be assigned to the 668 and 630 cm-1 bands 
390 (associated to the deformation mode (OOV) in the case of the lowest wavenumber). 
391 These assignments agree well with previous studies for peroxido heteroligand vanadate 
392 complexes.26
393 The IR spectra of the complexes exhibit a broad absorption band in the 3300-3400 cm-1 
394 region and the NH2 vibration bands cannot easily been assigned. Thus, lower frequencies 
395 of the FTIR spectra were analyzed. In relation to the presence of the NH2 group in the 
396 molecule, it is well known that the N-H bond in both, primary and secondary amines, are 
397 polar having a partial charge density on H and a negative partial charge density on N. This 
398 gives to the group the ability to form hydrogen bonds.27 In the Table 2 (Figure S2), the 
399 shifts of the bands assigned to vibrational modes of the NH2 group can be observed. 
400 According to the theoretical assignments, this band is actually composed of two 
401 contributions (NH2) and (CC) (Table 2) with varying intensity ratios. For 
402 [VO(O2)L(H2O)].H2O the ratio is 3:1 (NH2): (CC) in contraposition of the 1:1 
403 relationship for [VOL2H2O] and probably that is the reason why they appear with different 
404 intensities in the FTIR spectra. In addition, the possibility of neighboring interactions 
405 produced by the solid phase cannot be excluded. It can be noted that this combined band 
406 shifted to higher wavenumber in comparison with the sodium salt and the ligand, 
407 suggesting that the formation of the metallic complex provoked the rupture of the hydrogen 
408 bonds causing the increment of the wavenumber values as a consequence of the shortening 
409 of the NH bonds.28





































































































































410 3.2. Diffuse reflectance and UV/Vis spectroscopy. Solution stability.
411
412 The electronic spectra of the solids compounds and the behavior of the complexes in 
413 solution were studied using diffuse reflectance and UV-vis spectroscopy in order to 
414 characterize the complexes and to compare the species formed in solid phase with the 
415 species present in solution. 
416 Both complexes behaved as expected in solid phase and in solution. The solid 
417 peroxidovanadium(V) complex showed the typical bands associated with the CT of the 
418 amino and peroxo groups which appear at c.a. 455 nm, 385 nm and 318 nm (460 nm, 392 
419 nm and 314 nm from the fitting and deconvolution process; Figure 2(A) ((a) and (b), 
420 respectively).29 It is well known that UV-vis spectroscopy is a very useful tool for 
421 identification of mono- or di- peroxido complexes. The absence of the peroxido-vanadium 
422 charge transfer band (c.a. 220 nm) implies the presence of the peroxido vanadium species. 
423 Usually, peroxidovanadium(V) complexes showed one absorption band in the region 400-
424 460 nm and other CT band assigned to a L→M (peroxo to vanadium) (c.a. 325 nm) (Figure 
425 2A(a)). In addition, the calculations performed (considering the solution spectra) support 
426 these assignments. Based on the theoretical calculations (Figure 2 (B, b)), the observed 
427 characteristic bands in the UV-vis spectra can be assigned as follow: 400 nm (HOMO → 
428 LUMO, H-1 → LUMO), ligand charge transfer (aminobenzene and peroxo) to metal; 342 
429 nm (H-1 L+2), ligand charge transfer (peroxo) to metal; 293 nm (H-1 L+2, L+5), 
430 ligand charge transfer (peroxo) to ligand (aminobenzene) (Figure S3). The two last 
431 transitions are typical for peroxidovanadium species. Solution spectrum (2.7x10-3 M, DMF, 
432 Figure 2B(a)) showed similar pattern band with splitting of the band around 300 nm. The 
433 most intense bands are displayed at 303 nm ( = 525.9 M-1.cm-1), 330 nm ( = 540.7 M-
434 1.cm-1) and 407 nm ( = 129.6 M-1.cm-1). Similar pattern was obtained from the fitting and 





































































































































435 deconvolution process which is also consistent with the simulated solution spectrum 
436 (Figure 2 (A, B)).
437 The solid oxidovanadium(IV) complex usually shows d-d absorption bands. Three 
438 absorptions are expected: b2(dxy)→e (dxz, dyz) (1000-670 nm), b2(dxy)→b1 (dx2−y2) (667-
439 555 nm), b2(dxy)→a1 (dz2 ) (417-345 nm), being the last one usually overlapped for a 
440 charge transfer band from the ligand. In this case, the reflectance spectrum of the 
441 oxidovanadium(IV) complex showed two characteristic d-d bands, one located > 850 nm 
442 and other at 623 nm corresponding to the two lower energy transitions according to 
443 Ballhausen-Gray energy level scheme (Figure 3A).30 Solution spectrum (0.11 M, DMF) 
444 showed bands at 400-900 nm region which can be assigned to the electronic d-d- 
445 transitions of b2 → b1 (480 nm,  =25.18 M-1.cm-1) and b2 → e (864 nm,  = 27.54 M-1.cm-
446 1; 740 nm (shoulder,  = 23.72 M-1.cm- 1) (Figure 3B). Solvent effect, possibly caused by 
447 the replacement of the water molecule in the equatorial position, or axial coordination 
448 around the metal center, provoked a blue shift of these bands in comparison with the solid 
449 reflectance spectrum. The cis- conformation for the oxidovanadium(IV) complex is 
450 additionally supported by the calculated cis-UV/Vis spectrum. The spectrum of the cis-
451 conformation exhibits a good correlation with the experimental one (Figure 3C) having a 
452 similar pattern with two bands in opposition with the simulated for the trans-one. The 
453 observed splitting of the UV/Vis band is usually expected as a consequence of the 
454 symmetry lowering.31 According to the calculations, the bands were assigned to 733 nm 
455 (H-2 → L) and 548 nm (H-2 → L+4) and correlates reasonably well with the experimental 
456 spectrum (Figure S4).
457 Both complexes remained stable in a DMF and DMSO solutions (no appreciable 
458 changes were observed in the UV/Vis spectra, data not shown) at least during 1h. Then, it 





































































































































459 can be stated that the complex did not decompose during the manipulation of the solutions 
460 for the in vitro biological assays.
461
462 3.3. EPR spectroscopy
463
464 The suggested coordination mode in the oxidovanadiun(IV) complex interpreted by FTIR 
465 (Experimental and theoretical), diffuse reflectance and UV/Vis spectroscopy, and 
466 supported by the theoretical analysis was also substantiated by EPR measurements.
467 The X-band EPR powder spectrum of the [VOL2H2O] complex, recorded at room 
468 temperature, is shown in Figure 4A. The main feature is a broad and isotropic signal with a 
469 g0 value of 1.961 which is in concordance with a nearly axial ligand field as is usually 
470 observed for vanadium complexes owing vanadium-oxygen interactions (O-V-O) in the 
471 oxidovanadium(IV) unit.32 Some weaker signals are also observed superposed on the 
472 central line; they correspond to the hyperfine structure of a V(IV) isolated species (100% 
473 abundant 51V nucleus with I = 7/2). 
474 In order to establish the binding mode of the ligand and to identify the bioactive 
475 solution species of the [VOL2H2O] complex, EPR studies of the dissolved powder were 
476 performed. Figure 4B, shows the signal obtained in a DMF solution, at 298 K. The EPR 
477 signal shows the typical eight-line pattern spectrum for the oxidovanadium(IV) cation 
478 systems indicating the formation of single mononuclear species after the dissolution 
479 process. The spectral simulation, by the Bruker Simfonia program, predicted the formation 
480 of an oxidovanadium(IV) chromophore with spin Hamiltonian parameters of g0 = 1.988 
481 and A0 = 108.3 G (100.5 x 10-4 cm-1). This signal is coincident with the formation of 
482 oxidovanadium(IV) complexes with oxygen containing ligands and solvation at the cis- 





































































































































483 position in which the isotropic hyperfine coupling constant is larger than that obtained for 
484 the trans- isomer.33 The reduction of the hyperfine splitting constant value (A0) and the 
485 increment of the g0 parameter is expected, in comparison with those to the 
486 oxidovanadium(IV) free cation (V(IV)O2+, g0 = 1.964 and A0 = 106.3 x 10-4 cm-1),34 when 
487 negatively charged carboxylate groups are in the first coordination sphere. 
488
489 3.4. Biological activities
490 3.4.1. Acid (AcP) and alkaline (ALP) phosphatase inhibition assays
491
492 As mentioned above, researchers are excited in the development of chemotherapeutic 
493 agents.35 Simple salts and several vanadium(IV) and (V) complexes have demonstrated 
494 inhibition abilities against phosphatases.36 Based on this assumption, the inhibition ability 
495 of the peroxidovanadium(V) and oxidovanadium(IV) complexes were determined. 
496 In both assays, the activity of the free ligand, oxidovanadium(IV) sulfate and 
497 peroxidovanadium(V) species was also assessed. In Figure 5A it can be observed the AcP 
498 inhibition experiments. The free ligand had no inhibitory effect on AcP. The 
499 peroxidovanadium(V) complex did not inhibit phosphatase activity and its activity 
500 remained almost constant up to the higher tested concentrations (100-500 M). On the 
501 other hand, the oxidovanadium(IV) complex inhibits the enzymatic activity. It was less 
502 efficient than the oxidovanadium(IV) sulfate, resulting in a 50% of inhibition of the 
503 activity at a concentration of 250 μM (IC50). 
504 The data in Figure 5B showed the inhibitory effects of the compounds on the ALP 
505 at various concentrations. The ligand 4-aminobenzoic acid, the peroxidovanadium(V) 
506 species and the oxidovanadium(IV) complex showed no significant inhibition. 





































































































































507 Surprisingly, the peroxidovanadium(V) complex exerted better inhibition than the 
508 oxidovanadium(IV) sulfate salt from concentrations higher than 50 M reaching at a 50% 
509 of inactivation of the enzyme at 500 M concentration value. 
510 Amino derivative vanadium complexes demonstrated specific activity against 
511 phosphatases. The studied oxidovanadium(IV) complex behaves as a better inhibitor 
512 toward acid phosphatase, whereas peroxidovanadium(V) complex has superior inhibition 
513 effect on ALP. 
514 It would be possible to find tentative explanations for these behaviors based on the 
515 following considerations. In a previous work, McLauchlan et al36 performed a series of 
516 inhibition experiments on alkaline phosphatase (bovine calf intestine) and acid phosphatase 
517 (wheat germ) employing vanadium complexes containing the bidentate ligand picolinate 
518 and the metal in (III), (IV) and (V) oxidation states. They concluded about the relevance of 
519 the oxidation state and provided evidence that, in general, the most effective inhibitors are 
520 the complexes with an oxidation state of (V). Thus, one of the factors involved in the 
521 difference in the effect on ALP of [VOL2H2O] and [VO(O2)L(H2O)]·H2O complexes could 
522 possibly be associated to the oxidation state of vanadium. Indeed, it was proposed that for 
523 the alkaline phosphatase the complexes containing vanadium are more efficient in an 
524 oxidation state of (V).37 
525 It might also be thought that the optimum pH values for enzymatic action could be 
526 related to these differences in their activity. It is well known that oxidovanadium(IV) 
527 species are more stable close to neutral pH range in opposition to the effect of 
528 vanadium(V) species.38
529 Electronic nature of ancillary ligands is another factor that could be taken in 
530 consideration in the physiological effects of vanadium complexes. In experiments of 





































































































































531 cytotoxicity on Rat hepatoma H4IIEC3 cells, a series of peroxidovanadium(V) complexes 
532 with pentagonal-bipyramidal structure have been tested.39 It has been found that the IC50 
533 values are greater than those produced by a 1:1 mixture of hydrogen peroxide and sodium 
534 orthovanadate and concluded that the incorporation of organic ligand moderates the 
535 cytotoxicity of vanadium, and that the electronic properties of the peroxo group affected 
536 the physiological activity of the complexes. Ziegler et al. studied the inhibition potency of 
537 a series of systematically modified oxidovanadium(IV)--diketone complexes.40 They 
538 analyzed the inhibitory potency on calf-intestine alkaline phosphatase and correlated the 
539 calculated charge on VO unity with the effect of each metal complex. Their conclusion 
540 supports the idea that a more positive center led to the complex more tightly bound to the 
541 enzyme, and consequently behaving as a stronger inhibitor agent. If we assume this 
542 possibility and evaluate the calculated Mulliken charge on the VO group for [VOL2H2O], 
543 and compare the data with that calculated for the [VO(O2)L(H2O)]·H2O complex, these 
544 values are 0.50 and 0.64 (a.u.), respectively. Then, it can be proposed that 
545 peroxidovanadium(V) complex acts as a more positive center than oxidovanadium(IV) 
546 complex against ALP. Considering as well as the others factors, it can be assumed for 
547 neutral complexes that electron density on vanadium ion affects the enzyme interaction or 
548 the membrane transport.
549 In summary, the prevalence of oxidation state, the coordination number that 
550 complex adopts in solution, the pH and the electron density on VO group do possibly 
551 affect significantly their activities. We cannot discard others factors involved as the type of 
552 interaction, mechanism of inhibition, stability, etc., but further studies are needed to 
553 elucidate them.
554 It can also be mentioned that VO(O2)+ species was able to inhibit in a stronger 
555 manner the acid phosphatase (potato source), contrary to its effect on the acid phosphatase 





































































































































556 from wheat germ (Figure 5A).41 Furthermore, it is evident that peroxidovanadium(V) 
557 complex did not inhibit AcP. There is not so much information about inhibitory power of 
558 peroxidovanadium complexes, but potent inhibition on AcP has been related to the greater 
559 affinity of the inhibitors for imidazole nitrogen of the enzyme. Nevertheless, acid 
560 phosphatases from different sources may provide different inhibitions capacity for the 
561 same vanadium compound.42
562 Some aspects revealed in this work can be discussed in association with other 
563 previous reported vanadium-based phosphatase inhibitors (Table 3). To provide a 
564 comparative analysis, the presences of free NH groups as well as the influence of the 
565 phenyl group as part of the ligand were considered. Phenyl moiety was selected to explore 
566 if such types of compounds would be more portent inhibitors considering their structural 
567 relationship with phenol and the PNPP substrate. The formation of vanadate phenyl ester, 
568 produced an improvement of the inhibition ability of vanadate alone.43,44According to these 
569 studies, vanadate in presence of phenol significantly improved the inhibition potency on E. 
570 coli alkaline phosphatase due to the formation of species analogous to organic phosphate 
571 esters.44
572 The results of McLauchlan et al 36 demonstrated that, in the case of vanadium 
573 complexes containing the ligand imidazole-4-carboxylate (imc), the values for the 
574 Michaelis binding constant (Km) showed that VO(imc)2 complex had the lower Km = 3.3 
575 µM value denoting stronger affinity for wheat germen acid phosphatase and, the greater 
576 Km values were for ALP and PTP1B in opposition to the data observed for the VO2(imc)2- 
577 (Table 3). This affinity is comparable in some way to the results obtained in this work 
578 where the oxidovanadium(IV) complex behaved as a better inhibitor of the AcP and the 
579 peroxidovanadium(V) complex of the ALP. The anthranilate (2-aminobenzoate) vanadium 
580 complexes (VO(anc)2, VO2(anc)2-) worked in a similar way for PTP1B but not for AcP. 





































































































































581 These results are possible due to the lack of the free NH groups because contrasting 4-
582 aminobenzoate vanadium complexes they are involved in the coordination to the metal 
583 center. Structurally similar complexes with phenyl derivative ligands were VO(trop)2 and 
584 VO(hino)245 (Table 3). Both were tested on PTP1B denoting higher inhibition activity for 
585 the VO(hino)2 complex. The difference between the ligands is that the hino ligand has an 
586 additional –CH2(CH3)2 group attached to the benzoic moiety. This structural modification 
587 causes the reduction in 50 % of the IC50 value. VO(imc)2 and VO(hino)2 complexes could 
588 also be compared. Regardless the differences of the experimental method, Km value for 
589 VO(hino)2 is significantly lower (0.15 µM) than for VO(imc)2 (43 µM). The hypothesis 
590 concerning to the vanadium delivery to the active site of the enzyme could be the 
591 explanation of the inhibition ability of VO(hino)2. Possibly, the VO4 coordination sphere 
592 was more favorable for vanadate formation.4,12,36,44 Ligand selectivity is also observed 
593 when biguanide oxidovanadium(IV) complexes ([VO(Big)2].H2O, [VO(Big1)2].2H2O) 
594 were compared.46 The oxidovanadium complex that contain the phenyl group as part of the 
595 ligand acted as a better inhibitor on ALP than on PTP1B. Another example arises from the 
596 comparison between dioxidovanadium(V) complexes [VO2(L1)]2[(Et)3NH]2 (L1= 2,4-
597 (dihydroxyphenyl)ethylidene)benzohydrazide) and [VO2(L2)]2[(DBU-H)]2 (L2 = bis[(3-
598 hydroxy-5-(hydroxymethyl)-2-methylpyridin-4-l)methylene]oxalohydrazide).47The 
599 complex having L1 ligand was an efficient PTP1B inhibitor (Table 3). 
600 As it was stated, there is scarce information related to inhibition ability on AcP, 
601 ALP or PTPB1 of peroxidovanadium(V) complexes having a structurally related ligand to 
602 4-aminobenzoate anion. However, the following examples can be considered. Water-
603 soluble polymer matrices containing bis-peroxo vanadium complexes 
604 ([VO(O2)2(sulfonate)]-PSS, [V2O2(O2)4-(carboxylate)-VO(O2)2(sulfonate)]-PSSM) have 
605 been proved on ALP and contrasted with Na[VO(O2)2(H2O)] (Table 3).48 The 





































































































































606 bisperoxidovanadium(V) polymeric complexes were more effective than the 
607 peroxidovanadium(V) vanadium complex ([VO(O2)L(H2O)]). Interestingly, the peroxide 
608 species ([VO(O2)]+) did not inhibit intestinal ALP whereas the bisperoxide showed 
609 inhibitory activity (IC50=25.18 µM). This marked difference in reactivity may be possibly 
610 associated to the aqueous stability of perovanadates.49
611 Finally, the peroxido complexes [VO(O2)L(H2O)]·H2O (L=4-aminobenzoate) and 
612 NH4[VO(O2)(dipic)(H2O)]50·have acted as ALP inhibitors (Table 3). As it was shown, in 
613 [VO(O2)L(H2O)]·H2O the vanadium center is located in a pentagonal pyramid with a 
614 bidentate coordination mode of the peroxo and the carboxylate group including a water 
615 molecule in the equatorial position. In NH4[VO(O2)(dipic)(H2O)] complex the vanadium 
616 atom environment is a seven-coordinate distorted pentagonal bipyramid with the vanadyl 
617 oxygen and the water molecule at the apices and the peroxo group, nitrogen and two 
618 monodentate carboxylate groups in the pentagonal plane. It can be assumed that in solution 
619 the [VO(O2)L(H2O)]·H2O complex may adopt a seven coordinate structure similar to 
620 NH4[VO(O2)(dipic)(H2O)] thus it could be suggested that this type of structural 
621 arrangement around vanadium(V) tends to favor enzyme inhibition. 
622
623 3.4.42. Analysis of the inhibitory effect by FTIR spectroscopy
624(i) (i) Substrate (p-nitrophenylphosphate) bands 
625
626 The inhibition or the stimulation effect can be clearly seen by studying the FTIR changes 
627 in the finger print region (1230-840 cm-1) of the substrate (p-nitrophenylphosphate) 
628 corresponding to the phosphate group vibrations upon enzymatic or non-enzymatic 
629 hydrolysis.51





































































































































630 Lyophilized blank solution containing all the reactants, except ALP enzyme, 
631 showed the presence of the typical phosphate bands: 1115 cm-1, 1043 cm-1 and 981 cm-1 52 
632 (Figure 6). There was a drastic lowering in the 1115 cm-1 band intensity (50%) as a 
633 consequence of the ALP action on the phosphate hydrolysis. When the 4-aminobenzoic 
634 acid or the oxidovanadium(IV) complex were included in the reaction media, there was no 
635 significant changes in the intensity of the main band of the substrate observed at 1115 cm-1 
636 with respect to the control with ALP. There is some decrease in the intensity of the 980 cm-
637 1 band that may imply some kind of interaction between the phosphate group and those 
638 compounds. Besides, no interference with the corresponding bands of V=O) stretching 
639 frequencies of the oxidovanadium(IV) (965 cm-1) and peroxidovanadium(V) (998 cm-1) 
640 complexes has been observed, due to the low concentration of the complexes. In 
641 opposition, in the presence of the peroxidovanadium(V) complex, the spectrum showed 
642 that the intensity of the band related to the phosphate group did not significantly decrease 
643 in comparison with the spectrum of the blank, suggesting lack of the phosphate hydrolysis 
644 process in concordance with the inhibition effect. 
645 Unfortunately in the case of the AcP, the obtained FTIR spectra did not passed the 
646 quality test in order to be analyzed.
647
648 (ii) Conformational changes in the secondary structure of phosphatase enzymes
649
650 There are some studies that use FTIR spectroscopy to analyze the conformational 
651 changes that occur on the secondary structure of the phosphatases under different type of 
652 conditions as hyperbaric manipulation53, thermal and pH modifications54, interaction with 
653 some metal ions55 or with tartaric acid.56 It was known that the main spectral features of 





































































































































654 both enzymes are the characteristic strong Amide I band located at c.a. 1658 cm-1 which 
655 is indicative of the predominance of the α-helix conformation on the secondary 
656 structure.55,56 It is also well established that an attachment of any compound to the enzyme 
657 is able to produce conformational changes that can be observed by FTIR spectroscopy 
658 analyzing the different components of the Amide I band. In this section, a quantitative 
659 analysis of each conformational component such as -helix, -sheet, turns, solvate helix 
660 and random coil structures is provided in order to get a deeper insight about the possible 
661 modifications that the inhibitors provoke on enzyme structure.
662 As it can be seen from Table 4, the curve-fitting procedure based on the second 
663 derivative spectra indicated that the -helix content of the ALP control sample is about 
664 39.59%. The interaction of oxidovanadium(IV) complex and 4-aminobenzoic acid (non-
665 inhibitors) did not produced remarkable changes on the Amide I components. The -helix 
666 conformation slightly decreased (13-14%) whereas the most remarkable change is the 
667 increment in percentage of the -antiparallel structure. The observed losses of the 
668 percentages of -helix native structure, accompanied by the increment of the -antiparallel 
669 structure did not affect in a great extent the main conformation of the enzyme. This is 
670 consistent with the maintenance of the structure integrity of the ALP enzyme and its 
671 activity as a consequence. On the contrary, a drastic reduction in the -helix conformation 
672 (40%) was observed for the compounds that produced inhibition on the ALP activity 
673 (peroxidovanadium(V) complex). This loss of the -helix (un-solvated) conformation was 
674 cooperative with the gain of solvated -helix structure. Those changes can be explained in 
675 terms of the solvent accessibility. The native -helix (1650-1658 cm-1) is shown to be 
676 protected from the solvent by a tertiary fold. However, in the absence of this protection the 
677 helix become solvated and a spectral band at c.a. 1630 cm-1 appeared in the FTIR 





































































































































678 spectrum.57,58 It is then suggested that under the presence of inhibitors, the secondary 
679 structure of ALP became more flexible and more exposed. As a result, ALP allows the 
680 compounds to interact producing structural changes that block its activity. There was no 
681 presence of random coil structure component (1637-1645 cm-1) in the ALP analyzed 
682 samples. 
683 In the case of the AcP inhibitor, the oxidovanadium(IV) complex (Table 4), a 
684 rearrangement involving a lowering in the percentage contribution of α-helix and random 
685 coil structures, and a remarkable increment in the percentage of the solvated helix structure 
686 were produced. Again, the solvent accessibility could be involved but there was an 
687 additional structural modification: a decrease of 20% in the percentage of the random coil 
688 component that could led to AcP activity inhibition.
689
690 4. Albumin interactions
691
692 Because serum albumin is one of the most abundant transporter-protein in plasma, the 
693 affinity of drugs towards albumin can be correlated with a better accessibility to the target. 
694 Albumin plays an essential role in the increment of solubility and in the cellular delivery of 
695 compounds present in blood. For that reason the study of the interaction of selected 
696 compounds with the protein have significance in the binding properties of the complexes.
697 Fluorescence quenching experiments were performed for the peroxidovanadium(V) 
698 complex. The intensity of the complex band was negligible with respect to the band 
699 corresponding to its interaction with albumin. A decrease in the albumin fluorescence 
700 intensity was observed when measurements were performed at fixed BSA concentration (6 
701 M) and increasing concentrations of the peroxidovanadium(V) complex varying from 1 to 





































































































































702 100 M. The fluorescence quenching data were analyzed by the Stern-Volmer equation. 
703 The plot F0/F vs [Q] showed a positive deviation indicating the presence of both static and 
704 dynamic quenching59 by the same fluorophore (Figure 7, left). Assuming one type of 
705 quenching process at lower concentrations, Ksv constant were evaluated at the two 
706 temperatures (Figure 7, left, inset) and the calculated values were Ksv = 3.92 x 104 M-1 
707 (298K) and Ksv = 3.58 x 104 M-1 (310K). In addition, the quenching rate constant Kq could 
708 be estimated through the relationship Kq= Ksv/0 (0 = average lifetime of the biomolecule 
709 without quencher assumed to be 10-8 s for the fluorescence lifetime of the biopolymer). 
710 Then, both estimated Kq values 3.92 x 1012 M-1.s-1 (298K) and Ksv = 3.58x1012 M-1.s-1 
711 (310K) resulted higher than the maximum scatter collision quenching constant of various 
712 quenchers with the biopolymer (2 x 1010 M-1.s-1).47 Consequently, static type of quenching 
713 can be assumed involving a compound formation between the complex and BSA. 
714 Furthermore, from the plot log[(Fo-F)/F] versus log[Q] (Figure 7, right), the binding 
715 constants and the number of binding sites, were calculated being Kb = 2.29 ± 0.01 x 105 M-
716 1 (298K) and Kb = 1.82 ± 0.01 x 105 M-1 (303K), and n1 at both temperatures. It is well 
717 acknowledged that reversible binding to one high-affinity sites of the albumin is 
718 accompanied by association constant (Kb) values from 104 to 106 M−1 indicating a carrier-
719 like behavior.60 Thus, the Kb values of the complex suggested that it could be transported 
720 by BSA and that there were no significant differences in the binding ability at both 
721 temperatures. In addition, the value of n1 suggested that there is almost one class of 
722 binding site to peroxidovanadium(V) complex at BSA. Finally, to analyze the acting forces 
723 between the complex and albumin, thermodynamic parameters were evaluated, in which 
724 Go= -30.56 KJ/mol,    J/mol and So= 151.84 J/K.mol. The negative value of 
725 ΔG° indicates that the interaction of the complex with BSA is spontaneous and the driving 
726 force is mainly an entropic factor. The values of both ΔH° and ΔS° are positive, which 





































































































































727 suggested that the main contribution to these changes arise from hydrophobic 
728 interactions.61 
729 Due to the interference of 4-aminobenzoic acid and oxidovanadium(IV) complex in 
730 the fluorescence quenching experiments, their interaction with BSA was studied examining 
731 UV/Vis and 3D fluorescence spectra. 
732 UV/Vis spectroscopy is a simple method to investigate structural changes in BSA 
733 and determine complex formation. BSA shows a characteristic UV/Vis spectrum with two 
734 bands located at c.a. 220 and 280 nm. The band at higher energy can be correlated to 
735 n→π* transition of C=O in the backbone of the protein (peptide bonds) and the band at 
736 lower energy comes from the amino acid side chains (phenyl rings in Trp, Tyr and Phe 
737 residues) and both are sensitive to conformational changes.62
738 UV/Vis absorption measurements are shown in Figure 8. In the system ligand-BSA 
739 (Figure 8, A), increasing concentrations of the ligand lead to an increase and a shift to 
740 lower wavenumber of the BSA band located at 280 nm. This change can be attributed to 
741 the contribution of the band belonging to the ligand (263 nm). Indeed, a comparison of the 
742 ligand spectrum (20 M) mixed with BSA (6 M) showed the presence of two bands 
743 located at 268 and 283 nm in which the band belonging to BSA slightly its intensity 
744 (Figure 8 A, inset). For the complex, the interaction seems to be different. The complex did 
745 not show the band at 280 nm (Figure 8 C). The BSA band increased its intensity in 
746 contact with the complex and there was no significant change in the maximum at 280 nm 
747 (Figure 8 B). These behaviors correlated with hydrophobic type of interaction that may 
748 possible happen, due to a  stacking between aromatic ring of the complex and the 
749 phenyl rings of aromatic aminoacids residues in the protein. In addition, the band at 220 
750 nm slightly moved to higher wavelength suggesting changes in the polypeptide chain of 
751 BSA (Figure 8 B). 





































































































































752 Additional information can be obtained from the 3D fluorescence spectroscopy spectra. 
753 Peak 1 is the Rayleigh scattering peak (λex = λem). Peak A (λex = 280 nm, λem = 337.9 
754 nm) is representative of Trp and Tyr residues, and the fluorescence intensity of the residues  
755 related with the polarity of the microenvironment (Figure 9A). Peak B (λex = 230 nm, 
756 λem=340.7 nm) is associated to the polypeptide backbone structure. As can be seen from 
757 Figures 9B and 9C, and Table 5, Peak A increased its intensity for the ligand and the 
758 complex, in comparison to BSA. Although quenching behavior is usually expected, 
759 sometimes the increment of fluorescence intensity occurs and is suggested to be due the 
760 increase of the quantum efficiency of the compound. This behavior has been previously 
761 observed and associated to an intercalative action of the ligands and complexes with NH 
762 groups.63 It can be noted that the ligand 4-amino benzoic acid increased the intensity of 
763 Peak A more strongly than the complex. 
764 The most remarkable change was observed for Peak B (Table 5). In the presence of the 
765 oxidovanadium(IV) complex this peak practically disappeared, in contrast to the ligand 
766 which intensity increased once more. The decrease of the band produced by the complex 
767 has been associated with changes in the peptide strands (unfolding). This causes the 
768 exposition of hydrophobic regions, together with a lowering of the -helix content as a 
769 result of the impact of the interaction.64 Thus, different kind of interactions were produced 
770 by the ligand and the complex, in agreement with the different observations in the UV/Vis 




775 New oxidovanadium complexes containing vanadium(V) ([VO(O2)L(H2O)]·H2O) and (IV) 
776 ([VOL2H2O]) have been synthesized. The vanadium centers are both coordinated to 4-





































































































































777 aminobenzoic in a bidentate mode through carboxylate group. The proposed structures 
778 were supported by computational data analysis based in DFT theory. For the 
779 oxidovanadium(IV) complex a cis-conformation was assumed in concordance with FTIR, 
780 UV/Vis and EPR spectroscopies. Related to the biological in vitro assays, the amino 
781 derivatives complexes behaved in a selective way with respect to the phosphatases 
782 inhibition: [VOL2H2O] inhibited AcP, while [VO(O2)L(H2O)]·H2O inhibited ALP. This 
783 inhibitory behavior was contrasted using FTIR spectroscopy demonstrating that in the 
784 presence of peroxidovanadium(V) complex ALP was not able to hydrolyze phosphate 
785 group belonging to the p-NPP and that action may be due to the strong loss of the -helix 
786 conformation (40%) in the Amide I band. In this work we focused the study in the 
787 chemistry of the complexes, their ability to inhibit ALP or AcP and followed the inhibition 
788 action by using FTIR spectroscopy. However, further studies are needed to elucidate the 
789 mechanism, type of inhibition and stability. Albumin interaction was investigated for the 
790 ligand and both complexes. Peroxidovanadium(V) complex produced a quenching effect 
791 on the fluorescence spectrum of BSA and their binding constant value denoted a static 
792 quenching process. Both the ligand and the oxidovanadium(IV) complex produced an 
793 enhancement of its fluorescence intensity after albumin interaction and the changes were 
794 evaluated through 3D fluorescence experiments which showed a more drastic 
795 rearrangement for the metal complex, because of the disappearance of Peak B, associated 
796 to the protein polypeptide backbone structure.
797
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801 Electronic Supplementary Information. Figure S1. Structure and selected bond lengths 
802 (Å) and angles (o) for trans-[VOL2H2O] complex. Figure S2. FTIR spectra of 4-
803 aminobenzoic acid, sodium aminobenzoate, [VOL2H2O] and [VO(O2)L(H2O)].H2O. 
804 Figure S3. Calculated bands in the UV-vis spectra of [VO(O2)L(H2O)].H2O. Figure S4. 
805 Calculated bands in the UV-vis spectra of [VOL2H2O]. Figure S5, S6 and S7. Contour 
806 spectra and three-dimensional fluorescence spectra of 6 M BSA, 6 M BSA-20 M 4-
807 aminobenzoic acid and 6 M BSA-20 M [VOL2H2O], respectively. 
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Tris-HCl Tris(hydroxymethyl)aminomethane hydrochloride 
820
821







































































































































825 Figure 1. Optimized geometry at the level of theory B3LYP/6-311+g* of oxidovanadium 
826 complexes: [VO(O2)L(H2O)].H2O (A, left) and cis-[VOL2H2O] (B, right). 
827
828 Figure 2. [VO(O2)L(H2O)].H2O complex: (A) (a) Diffuse reflectance spectrum in the 220-
829 550 nm region, (b) peak fitting procedure with contribution of three involved bands; (B) 
830 (a) Electronic absorption spectra in the 260-600 nm region (2.7 x 10-3M, DMF), (b) 
831 calculated spectrum, (c) peak fitting procedure with contribution of three involved bands.
832
833 Figure 3. [VOL2H2O] complex: (A) Diffuse reflectance spectrum in the 220-850 nm 
834 region, (B) Electronic absorption spectra in the 425-890 nm region (0.11 M, DMF), (C) 
835 Calculated cis and trans spectra.
836
837 Figure 4. (A) Powder EPR spectrum of [VOL2H2O] obtained at 77 K, frequency 9.42 
838 GHz; (B) Sample dissolved in DMF, at room temperature, in quartz flat cell, frequency 
839 9.70 GHz.
840
841 Figure 5. Effect of 4-aminobenzoic acid (▼), VOSO4.5H2O (■), [VO(O2)L(H2O)].H2O 
842 (▲), [VO(O2)]+ (♦) and [VOL2H2O] (●) on (A) on AcP activity and (B) ALP activity. The 
843 values are expressed as the mean ± SEM of at least three independent experiments. 
844 *significant values in comparison with the basal level (p < 0.05)
845





































































































































846 Figure 6. FTIR changes in the finger print region (1230-840 cm-1) of the substrate PNPP 
847 (4-nitrophenylphosphate): Liophilizated blank solution containing all the reactant except 
848 ALP enzyme (solid line); liophilizated blank solution containing all reactants including 
849 ALP enzyme (Dash line); all the reactant + [VO(O2)L(H2O)].H2O (■), all the reactant + 
850 [VOL2H2O] (●) ; all the reactant + 4-aminobenzoic acid (L, ▲).
851
852 Figure 7. [VO(O2)L(H2O)].H2O: left: Stern-Volmer plot F0/F vs [Q], right: Plot of log 
853 [(F0-F)/F] vs log [Q]. 
854
855 Figure 8. UV-Vis spectra in the 220-300 nm region: (A) 4-aminobenzoic acid-BSA system 
856 (inset: deconvolution of the 280 nm band), (B): [VOL2H2O]-BSA system (6 M BSA, 
857 increasing concentrations of ligand and complex from 0-60M), (C): solid line: 6 M 
858 BSA, short dash: 6 M BSA-20 M aminobenzoic acid, gray line: 20 M 4-aminobenzoic 
859 acid, dotted line: 6 M BSA-20 M [VOL2H2O], dash dot line: 20 M [VOL2H2O].
860
861 Figure 9. Three-dimensional fluorescence spectra of 6 M BSA, 6 M BSA-20 M 4-
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1048 Table 1. Selected bond lengths (Å) and angles (o) around vanadium in the aminobenzoate 
1049 (L) oxidovanadium complexes complex calculated at B3LYP 6-311+g*level of theory.




Bond lengths (Å) angles (o) Bond lengths (Å) angles (o)
V-O1 1.597 O1VO2 110.2 V-O1 1.589 O1VO2 107.4
V-O2 2.016 O1VO3 108.5 V-O2 1.998 O1VO3 98.3
V-O3 2.017 O1VO4 103.2 V-O3 2.060 O1VO4 109.9
V-O4 2.021 O1VO5 158.9 V-O4 1.826 O1VO5 109.1
V-O5 2.269 O1VOw 93.8 V-O5 1.834 O1VOw 97.2
V-Ow 2.129 O2VO3 65.3 V-Ow 2.122 O2VO3 64.3
O2VO4 144.9 O2VO4 133.4
O2VO5 88.7 O2VO5 138.5
O2VOw 93.4 O2VOw 76.4
O3VO4 94.3 O3VO4 83.4
O3VO5 87.5 O3VO5 127.4
O3VOw 153.1 O3VOw 140.5
O4VO5 60.9 O4VO5 45.6
O4VOw 95.0 O4VOw 124.3
O5VOw 75.2 O5VOw 80.2





































































































































1053 Table 2. Characteristic FTIR bands for 4-aminobenzoic acid), its sodium salt, 


























 1603(m) 1637.82 
1600(s) 1591(s) 1604(br.s) 1626.06 
1615.11


















1429(s) 1434.09 s(COO-), (CC),


























1072(w) 1083(m) 1101(m) 1151.67
1073.24
1069(w) 1055.09 CC), NC)
965(s) 1007.74  (V=O)
1017(m) 1021.06 CCC)






































































































































901(w) 884.92 CCC), OCO) CC),
871(m) 865.84 (HCCC), (CCCC), 
(OCOC) 
853(m) 868.90 (HCCC), (OCOC)
 CCC), (NCCC)
CCC)
844(m) 838.75 CCC), OCO)
829(m) 838.93 CC),  OCO), CCC)
 OCO), CCC)
769(m) 803.42 (CCV), 
 (HCCC), (OCOC)














566.08 (CCO) (COV), (H2O)
507(w) 502.18 HOVC)
 478.62 (V-C), HOVC)
1056 vs= very strong, s = strong, m = media, w = weak, vw = very weak, sh=shoulder,  = 
1057 stretching,  = in-plane bending,  = out-of-plane bending, torsion.
1058





































































































































1059 Table 3. IC50 and Km data values for a series of vanadium(IV) and (V) complexes 
1060 containing NH group and/or comprising phenyl group structurally related to PNPP 
1061 substrate.
1062
1063 aWheat Germen, b´Potato source, cBovine calf intestine, MOPS pH = 7 for biguanido complexes 
1064 and , dALP = rabbit intestine, eALP = chicken intestine, PTP1B = Protein-tyrosine phosphatase 1B.
1065 L = 4-aminobenzoate, imc = imidazole-4-carboxylate, anc = anthranilate (2-aminobenzoate); trp = 
1066 tropolonato; hino = hinokitolonato, dipic = dipicolinic acid. HBig.HCl= N´,N´-dimethylbiguanide 
1067 hydrochloride, Big1= phenformin, see scheme. PSS = poly(sodium 4-styrene sulfonate), PSSM = 
1068 poly(sodium styrene sulfonate-co-maleate)]. L1= 2,4-(dihydroxyphenyl)ethylidene)benzohydrazide, 
1069 L2 = bis[(3-hydroxy-5-(hydroxymethyl)-2-methylpyridin-4-l)methylene]oxalohydrazide; (Et)3NH = 
1070 triethylamine; DBU = 1,8-diazabicyclo[5.4.0]undec-7-ene. 
Phosphatase Compound IC50(µM) Km (µM)
VO(imc)2 - 3.3 [36]
VO2(imc)2- - 33 [36]
VO(anc)2 - 23 [36]
AcPa
(sodium acetate, 
pH=4.8) VO2(anc)2- - 0.25 [36]
V(IV)O2+ 67.37 - This work
[VO(O2)]+ 63.45 - This work
[VOL2H2O] 250 - This work
AcPb´
(acetate, pH=5.6)
[VO(O2)L(H2O)] No inhibition This work
VO(imc)2, - 15.0 [36]
VO2(imc)2- - 12.6 [36]
VO(anc)2 - 68 [36]
[VO(Big)2].H2O, 33 - [44]
[VO(Big1)2].2H2O 17 - [44]
V(IV)O2+ >500 M - This work
[VO(O2)]+ No inhibition - This work
[VOL2H2O] No inhibition - This work
ALPc
(Tris, pH=7.8)
[VO(O2)L(H2O)] 500 M - This work
Na[VO(O2)2(H2O)] 25.18 9.13 [47]





(HEPES, pH=8) NH4[VO(O2)(dipic)(H2O)]] - 13.0 [49]
VO(imc)2 - 43 [36]
VO2(imc)2- - 12.5 [36]
VO(anc)2 - 56.7 [36]
PTP1B 
(HEPES, pH=7.3)
VO2(anc)2- - 19.3 [36]
[VO(Big)2].H2O, 8.6 x 10-4 - [45]




VO(hino)2 0.27 0.15 [43]
[VO2(L1)]2[(Et)3NH]2 1.51 [46]PTP1B
(imidazole, pH = 7.0) [VO2(L2)]2[(DBU-H)]2 lower inhibition [46]





































































































































1071 Table 4. FT-IR/ATR determination of secondary structure percentages of (i) ALP (glycine 
1072 buffer pH=10.5) and (ii) AcP (acetate buffer) of the systems containing ALP with 4-
1073 aminobenzoic acid (ALP-L), V(IV)O2+ (ALP-VO), oxidovanadium (ALP-[VOL2H2O]) and 
1074 peroxidovanadium (ALP-[VO(O2)L(H2O)].H2O) compound (500 M). 
1075











3.41±0.03 9.74±0.07 8.21±0.06 8.94±0.07
Turns
1666-1673
10.99±0.13 6.20±0.05 8.82±0.07 7.57±0.03
α-helix
1650-1658







24.9±0.29 29.87±0.31 30.17±0.36 36.77±0.22
β-sheet
1613-1625










7.60±0.20 13.05±0.27 14.87±0.23 12.94±0.25
Turns
1666-1673
16.95±0.31 9.98±0.17 15.10±0.32 12.02±0.19
α-helix
1650-1658








5.31±0.03 5.35±0.08 21.85±0.27 3.26±0.10
β-sheet
1613-1625
8.98±0.18 16.65±0.33 5.97±0.16 12.97±0.26





































































































































1078 Table 5: 3D Fluorescence Spectral Parameters of BSA, 4-amino benzoic acid-BSA and 
















Peak position ex/em (nm/nm) ∆ Intensity
Peak A 280/337.9 57.9 4956.4
Peak B 230/340.7 110.7 575.8
4-amino benzoic acid-BSA system 
Peak position ex/em (nm/nm) ∆ Intensity
Peak A 280/335.5 55.5 5721.2
Peak B 230/337.5 107.5 644.6
Oxidovanadium(IV)complex-BSA system 
Peak position ex/em (nm/nm) ∆ Intensity
Peak A 280/337.2 57.2 5340.3
Peak B 230/- - -
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